The identification of novel combinations of angiogenic targets to enhance the therapeutic index of anti-VEGF/VEGFR-2 strategies remains paramount, however, on account of cancers developing numerous adaptive mechanisms to escape tumor therapy (7). This evidence concerns the gene VEGFA and cancer.